Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices
Precigen and the Recurrent Respiratory Papillomatosis Foundation marked the third annual International RRP Awareness Day by sharing patient and caregiver stories. The release reiterates that Precigen’s HPV-specific immunotherapy was approved by the FDA in August 2025 as the first and only treatment for adults with RRP.
Key figures
- Us adult rrp patients
- 27000
- Global adult rrp patients
- 170000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.